Anika Therapeutics (ANIK) Depreciation & Amortization (CF) (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $1.4 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 1.74% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 17.4% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, down 21.96% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.4 million, up from $1.3 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for ANIK reached as high as $1.9 million in Q3 2024 and fell as low as $1.3 million in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $1.6 million in 2023.
• Across the five-year window, Depreciation & Amortization (CF) grew 16.54% in 2024 and fell 26.01% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.7 million in 2022, then declined by 5.35% to $1.6 million in 2023, then declined by 4.18% to $1.6 million in 2024, then fell by 15.51% to $1.3 million in 2025, then climbed by 6.75% to $1.4 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.